Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Bienvenido S Balotro

Bienvenido S Balotro

University of the Philippines Manila, Philippines

Title: Characterization of Verapamil Hydrochloride entrapped in poly (lactide-co-glycolide) (PLGA) particles

Biography

Biography: Bienvenido S Balotro

Abstract

Background: Verapamil hydrochloride is a commonly prescribed drug in the management of hypertension, angina, and cluster headache prophylaxis. Verapamil hydrochloride suffers from the disadvantage of low bioavailability because of extensive hepatic metabolism (only 10% to 20% becomes bioavailable) and short half-life (2 to 4 hours). As a result, it requires frequent dosing of the drug leading to the problem of noncompliance in patients and alternating over and under doses of the drug. A method of circumventing hepatic first pass effect is by making the drug particle microsized(<10µm) and lipophilic.

Objectives: The aim of this study was to characterize the optimized microparticles of Verapamil hydrochloride entrapped in Poly (lactide-co-glycolide) (PLGA) (Verapamil HCl-PLGA) prepared through solvent displacement method followed by lyophilization.

Significance: This study sought to contribute to the improvement of the dosage form of Verapamil HCl by the application of polymeric drug delivery system. Through polymeric drug formulation, the low bioavailability due to hepatic first-pass effect is addressed by the transport of hydrophobic polymeric microparticles (size of <10µm) to the lymphatic system instead of the hepatic portal transport, therefore, avoiding extensive hepatic metabolism.

Methodology: The Verapamil HCl-PLGA microparticles were prepared through solvent displacement method followed by lyophilization. The optimization parameters for the formulation include particle size, polydispersity index, zeta potential, and entrapment efficiency. The optimized final formulation was further characterized based on percent (%) particle recovery, redispersibility, percent (%) drug loading, drug release kinetics, and morphology.

Results:  Based on the analysis of the data from solvent displacement method, increasing The PLGA 75:25 concentration resulted to an increase in the particles size, polydispersity index and entrapment efficiency, and a decrease in zeta potential; while the increase in Poloxamer 188 concentration led to a decrease in zeta potential and an increase in the entrapment of the drug; lastly, the increase in the pH of the non-solvent phase resulted to an increase in particle size. The addition of sucrose, led to a unfavorable increase in the particle size and polydispersity index, and a decrease in zeta potential and entrapment efficiency after lyophilization. The final product of the process was a heterogenous sized (<10µm) irregularly shaped particles (fragment-like), with an acceptable particle recovery, redispersibility, and percentage (%) drug loading, but poor release kinetic property (non-linear and decreasing concentration over time).

Conclusion:  The Verapamil HCl-PLGA microparticles prepared through solvent displacement method followed by lyophilization were able to meet the conditions noted by Chu and Lui (2008) for lymphatic transport: entrapment in a lipophilic polymer in terms of particle size requirement (<10µm).